comparemela.com

Page 2 - Jeffrey Wade News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) Q2 2023 Earnings Call Transcript

After FDA Miss in Diabetes, Lexicon Lands Long-Awaited Approval in Heart Failure

Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.

vimarsana © 2020. All Rights Reserved.